Table 3.

Clinical trials of immune checkpoint inhibitors in combination with Antiangiogenic agents in advanced NSCLC

Clinical trial	Patients	Targeted Agent	Immunotherapy	Phase	Status
NCT01454102 (CheckMate 012)	Newly diagnosed and confirmed Stage IIIB/IV NSCLC	bevacizumab	nivolumab	I	Active, not recruiting
NCT02574078 (CheckMate 370)	Histologically confirmed locally advanced or stage IV NSCLC	bevacizumab	Nivolumab	I/II	Active, not recruiting
NCT02681549	Anti-PD-1/PD-L1-naïve biopsy proven metastatic melanoma or non-squamous NSCLC with at least one untreated brain metastasis	bevacizumab	Pembrolizumab	II	Recruiting
NCT02039674 (KEYNOTE- 021)	Newly diagnosed stage IIIB/IV NSCLC, progression >1 year after adjuvant therapy for stages I–IIIA NSCLC and no systemic therapy for the recurrent disease	bevacizumab	Pembrolizumab	I/II	Active, not recruiting Has Results
NCT02366143 (IMpower 150)	Treatment-naïve Histologically or cytologically confirmed, stage IV non-squamous NSCLC	bevacizumab	Atezolizumab	III	Active, not recruiting
NCT02856425 (PEMBIB)	Pretreated advanced solid tumors including LA/stage IV/locally recurrent NSCLC of adenocarcinoma and squamous	Nintedanib	Pembrolizumab	I	Suspended
NCT02443324	Metastatic or locally advanced, unresectable solid tumors including NSCLC progression after 0–3 prior lines of systemic therapy	Ramucirumab	Pembrolizumab	I	Active, not recruiting
NCT02572687	LA/unresectable/metastatic/unresectable solid tumors including pretreated NSCLC	Ramucirumab	Durvalumab	I	Active, not recruiting
NCT02174172	LA/metastatic solid tumors including LA/stage IV NSCLC, participants with sensitizing EGFR mutations or ALK rearrangements must have failed or are intolerant to prior treatment with EGFR or ALK inhibitors	bevacizumab	Atezolizumab	I	Active, not recruiting
NCT03786692	Stage IV NSCLC, Patients with targetable driver mutations (in EGFR, ALK, or, ROS1) must have received prior treatments with one or more TKIs.	bevacizumab	Atezolizumab	II	Not yet recruiting
NCT03169738	NSCLC with progression on or after treatment with PD-1/PD-L1 inhibitors	bevacizumab	Nivolumab	Ib/II	Not yet recruiting
NCT03836066	Locally Advanced or Metastasic High-intermediate Tumor Mutation Burden Selected Non-squamous NSCLC Patients	bevacizumab	Atezolizumab	II	Not yet recruiting
NCT03713944	Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous NSCLC	bevacizumab	Atezolizumab	II	Recruiting
NCT03616691	Stage IIIb, IV or recurrent non-squamous cell NSCLC After Failure With Platinum-Containing Chemotherapy	bevacizumab	Atezolizumab	II	Not yet recruiting
NCT03647956	Stage IIIB or IV NSCLC Patients After Failure of EGFR-TKIs	bevacizumab	Atezolizumab	II	Recruiting
NCT03786692	Stage IV NSCLC Patients Who Have Never Smoked or Have a Driver Mutation	bevacizumab	Atezolizumab	II	Not yet recruiting
NCT03735121	Pre-treated locally advanced or metastatic NSCLC	bevacizumab	Atezolizumab	Ib/II	Recruiting
NCT03527108	Pre-treated Recurrent, Advanced, Metastatic	Ramucirumab	Nivolumab	II	Not yet recruiting
NCT03689855 (RamAtezo-1)	NSCLC After Progression on Any Immune Checkpoint Blocker	Ramucirumab	Atezolizumab	II	Not yet recruiting
NCT03377023	Advanced/metastatic Non-Small Cell Lung Cancer (NSCLC) with no curative treatment options	Nintedanib	Nivolumab	I/II	Recruiting

Abbreviations: ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; HR, hazard ratio; NSLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor; LA, locally advanced.